TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06905210: Phase III Superiority, Randomized, Double-blind, Placebo-controlled, Adaptive, Multicenter Study to Compare the Efficacy and Safety of a New Concentration of an Antiandrogenic Progestogen Combined With a Reduced-dose Est

Sponsor: Eurofarma Laboratorios S.A. · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 531 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,924,204

Rescue Site Savings

+$4,579,500

Unlock Full NCT06905210 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06905210 Rescue Dossier →